Johnson & Johnson Enters New Era in Solid Tumors at ESMO 2025 with Promising Data Across Multiple Cancer Types

Johnson & Johnson is set to showcase 16 presentations at the European Society for Medical Oncology (ESMO) 2025 Congress, highlighting advances across its industry-leading solid tumor pipeline. The company has entered a new era in oncology, delivering bold advances in solid tumors, including head and neck, lung, bladder, and prostate cancers. According to Johnson & Johnson, the company's solid tumor pipeline has demonstrated accelerating momentum and a commitment to transforming care in some of the most challenging and underserved cancers.

Key Takeaways:

• Johnson & Johnson will showcase 16 presentations at ESMO 2025 Congress, highlighting advances in its solid tumor pipeline, including head and neck, lung, bladder, and prostate cancers.
• The company has received Fast Track designation for pasritamig, a first-in-class bispecific T-cell-engaging antibody targeting human kallikrein 2 (KLK2) in patients with metastatic castration-resistant prostate cancer.
• Johnson & Johnson has delivered compelling clinical activity in recurrent or metastatic head and neck cancer with subcutaneous amivantamab, building on its strength in colorectal cancer and EGFR-mutated lung cancer.
• The company has made significant progress in solid tumor research, with studies across four different solid tumor types: head and neck cancer, non-small cell lung cancer, prostate cancer, and bladder cancer.
• Johnson & Johnson has entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GlaxoSmithKline [GSK] in 2019) for exclusive rights to niraparib in prostate cancer.
• The company has received approval for niraparib and abiraterone acetate in several countries for the treatment of patients with metastatic castration-resistant prostate cancer.

Statistics:

• Johnson & Johnson will showcase 16 presentations at ESMO 2025 Congress.
• The company has delivered compelling clinical activity in recurrent or metastatic head and neck cancer with subcutaneous amivantamab in 10% of patients.
• Johnson & Johnson has received Fast Track designation for pasritamig, a first-in-class bispecific T-cell-engaging antibody targeting human kallikrein 2 (KLK2) in patients with metastatic castration-resistant prostate cancer.

Sources:

• Johnson & Johnson: "Johnson & Johnson Enters New Era in Solid Tumors at ESMO 2025 with Promising Data Across Multiple Cancer Types"
• Johnson & Johnson: "Johnson & Johnson issued the following news release: First report of subcutaneous amivantamab demonstrates compelling clinical activity in recurrent or metastatic head and neck cancer, building on strength in colorectal cancer and EGFR-mutated lung cancer"
• European Society for Medical Oncology (ESMO): "ESMO 2025 Congress"